India presents Qartemi, a profitable car-t cell therapy for non Hodgkin lymphoma of B cells, offered by New Hope with a success rate of 83.3%.
India presents a new CAR-T cell therapy To treat non Hodgkin lymphoma (B-NHL). NHL is a type of Blood cancer That affects B cells. This new treatment approach is called Bitch Developed by Immuneel Therapeutics, a Biotechnology company based in Bengaluru.
Advertisement
What makes Qartemi special?
Unlike regular medications based on chemicals, Qartemi is a “living medication” made of patient’s cells. The cells are taken from the patient and genetically modify to strengthen their immune response. Then it is reintroduced in the body of the patient that is directed and destroyed the cancer cells.
Qartemi is a personalized chimeric antigen receptor (CAR) -Therapy Totherapy adapted to the condition of each patient. India informs about 1.2 LAKH of new cases of blood cancer every year, with more than 70,000 deaths. Patients with aggressive B-NHL forms cannot obtain adequate treatment and cure.
Traditional treatments such as chemotherapy and radiation often fail in cases of refractory blood cancer. However, Qartemi offers a new opportunity for survival.
Advertisement
Qartemi -clinical trials in India
Qartemi was tested in leading hospitals such as Narayana Health (Bengaluru), Apollo Cancer Hospital (Chennai) and PGimer (Chandigarh) under the “Imagine” clinical trial program. The results were promising, showing a success rate of 83.3% in the treatment of patients.
The Indian government also supported this investigation through Birac (Biotechnology Industry Research Assistance Council). CAR-T therapy is an expensive treatment, which costs ₹ 3-5 million rupees. But Qartemi has a price between ₹ 35-50 Lakh, which makes it much more affordable for Indian patients.
Advertisement
Where can patients get Qartemi?
This revolutionary therapy is now available in the best hospitals in India, which include:
- Narayana Health
- Apollo hospitals
- CMC Velore and Ludhiana
- Manipales hospitals
- Rajiv Gandhi Cancer Institute, Delhi
- SGPGI, Lucknow
- Amrito Hospital, Faridabad
Qartemi was developed with experience in Hospital Clínic in Barcelona, a world renowned institution in cancer treatment. This marks the first International Car-T cell therapy of India, which shows that India is at the advanced avant-garde Cancer treatments. With Qartemi now available, thousands of patients with blood cancer in India have a new hope.
Means of origin
